{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:37:55Z","timestamp":1794872275309,"version":"4.9.1"},"reference-count":315,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is a hematological malignancy defined by the abnormal proliferation and accumulation of plasma cells (PC) within the bone marrow (BM). While multiple myeloma impacts the bone, it is not classified as a primary bone cancer. The bone marrow microenvironment significantly influences the progression of myeloma and its treatment response. Mesenchymal stromal cells (MSCs) in this environment engage with myeloma cells and other bone marrow components via direct contact and the secretion of soluble factors. This review examines the established roles of MSCs in multiple facets of MM pathology, encompassing their pro-inflammatory functions, contributions to tumor epigenetics, effects on immune checkpoint inhibitors (ICIs), influence on reprogramming, chemotherapy resistance, and senescence. This review investigates the role of MSCs in the development and progression of MM.<\/jats:p>","DOI":"10.1186\/s12935-025-03741-x","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T12:17:44Z","timestamp":1742991464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword"],"prefix":"10.1186","volume":"25","author":[{"given":"Sina","family":"Kamrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Naseramini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Khani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Sadat","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Afkhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Atashzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Alavimanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzane","family":"Saeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ronaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"8","key":"3741_CR1","first-page":"1","volume":"84","author":"AS Hong","year":"2023","unstructured":"Hong AS, Muthian S, Banerjee L. Plasma cell myeloma in the distal appendicular skeleton. Br J Hosp Med (Lond). 2023;84(8):1\u20132.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"2","key":"3741_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s12276-024-01168-4","volume":"56","author":"S Tian","year":"2024","unstructured":"Tian S, et al. Nucleus pulposus cells regulate macrophages in degenerated intervertebral discs via the integrated stress response-mediated CCL2\/7-CCR2 signaling pathway. Exp Mol Med. 2024;56(2):408\u201321.","journal-title":"Exp Mol Med"},{"issue":"1","key":"3741_CR3","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1186\/s12967-024-05900-6","volume":"22","author":"Z Huang","year":"2024","unstructured":"Huang Z, et al. Cellular crosstalk in the bone marrow niche. J Transl Med. 2024;22(1):1096.","journal-title":"J Transl Med"},{"issue":"1","key":"3741_CR4","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1038\/s41467-024-46594-0","volume":"15","author":"RT Bishop","year":"2024","unstructured":"Bishop RT, et al. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease. Nat Commun. 2024;15(1):2458.","journal-title":"Nat Commun"},{"key":"3741_CR5","doi-asserted-by":"crossref","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Frontiers in Endocrinology; 2019. p. 9.","DOI":"10.3389\/fendo.2018.00788"},{"issue":"1","key":"3741_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41375-024-02453-x","volume":"39","author":"IL Boueya","year":"2025","unstructured":"Boueya IL, et al. Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia. Leukemia. 2025;39(1):8\u201324.","journal-title":"Leukemia"},{"key":"3741_CR7","doi-asserted-by":"publisher","first-page":"117537","DOI":"10.1016\/j.biopha.2024.117537","volume":"180","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Unveiling the immunogenicity of allogeneic mesenchymal stromal cells: challenges and strategies for enhanced therapeutic efficacy. Biomed Pharmacother. 2024;180:117537.","journal-title":"Biomed Pharmacother"},{"key":"3741_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.18632\/oncotarget.28672","volume":"15","author":"T Minev","year":"2024","unstructured":"Minev T, et al. Mesenchymal stem cells - the secret agents of cancer immunotherapy: promises, challenges, and surprising twists. Oncotarget. 2024;15:793\u2013805.","journal-title":"Oncotarget"},{"key":"3741_CR9","doi-asserted-by":"publisher","first-page":"1255697","DOI":"10.3389\/fcell.2023.1255697","volume":"11","author":"H Afkhami","year":"2023","unstructured":"Afkhami H, et al. New insights in application of mesenchymal stem cells therapy in tumor microenvironment: pros and cons. Front Cell Dev Biology. 2023;11:1255697.","journal-title":"Front Cell Dev Biology"},{"issue":"1","key":"3741_CR10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s12672-024-01590-0","volume":"15","author":"H Afkhami","year":"2024","unstructured":"Afkhami H, et al. Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents\u2014challenges and limitations. Discover Oncol. 2024;15(1):818.","journal-title":"Discover Oncol"},{"key":"3741_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.reth.2024.08.001","volume":"26","author":"H-J Liao","year":"2024","unstructured":"Liao H-J, et al. Harnessing the potential of mesenchymal stem cells\u2013derived exosomes in degenerative diseases. Regenerative Therapy. 2024;26:599\u2013610.","journal-title":"Regenerative Therapy"},{"key":"3741_CR12","doi-asserted-by":"crossref","unstructured":"Aliniay-Sharafshadehi S et al. Exploring the therapeutic potential of different sources of mesenchymal stem cells: novel approach to combat burn wound infections. Front Microbiol. 15: p. 1495011.","DOI":"10.3389\/fmicb.2024.1495011"},{"key":"3741_CR13","doi-asserted-by":"publisher","first-page":"1251956","DOI":"10.3389\/fmicb.2023.1251956","volume":"14","author":"E Andalib","year":"2023","unstructured":"Andalib E, et al. Application of hypoxia-mesenchymal stem cells in treatment of anaerobic bacterial wound infection: wound healing and infection recovery. Front Microbiol. 2023;14:1251956.","journal-title":"Front Microbiol"},{"issue":"5","key":"3741_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4252\/wjsc.v15.i5.421","volume":"15","author":"D Garc\u00eda-S\u00e1nchez","year":"2023","unstructured":"Garc\u00eda-S\u00e1nchez D, et al. Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression. World J Stem Cells. 2023;15(5):421\u201337.","journal-title":"World J Stem Cells"},{"key":"3741_CR15","doi-asserted-by":"publisher","first-page":"119643","DOI":"10.1016\/j.lfs.2021.119643","volume":"279","author":"M Mahjoor","year":"2021","unstructured":"Mahjoor M, et al. MicroRNA-30c delivered by bone marrow-mesenchymal stem cells induced apoptosis and diminished cell invasion in U-251 glioblastoma cell line. Life Sci. 2021;279:119643.","journal-title":"Life Sci"},{"issue":"7","key":"3741_CR16","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1007\/s00432-022-04123-w","volume":"149","author":"M Mahjoor","year":"2023","unstructured":"Mahjoor M, et al. The role of microRNA-30c in targeting Interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: a therapeutic approach in colorectal cancer. J Cancer Res Clin Oncol. 2023;149(7):3149\u201360.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3741_CR17","doi-asserted-by":"publisher","first-page":"104024","DOI":"10.1016\/j.yofte.2024.104024","volume":"88","author":"F Akbari","year":"2024","unstructured":"Akbari F, et al. Monitoring optogenetic stimulation of light-sensitive stem cells using a twin-core fiber-based Mach-Zehnder interferometer. Opt Fiber Technol. 2024;88:104024.","journal-title":"Opt Fiber Technol"},{"key":"3741_CR18","doi-asserted-by":"crossref","unstructured":"Iancu-Rubin C, Weinberg RS. Overview of cellular Therapy, in Transfusion medicine and hemostasis. Elsevier; 2025. pp. 417\u201322.","DOI":"10.1016\/B978-0-323-96014-4.00112-9"},{"issue":"1","key":"3741_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11033-024-10174-8","volume":"52","author":"M Stanis\u0142awowski","year":"2025","unstructured":"Stanis\u0142awowski M. Effect of adipose tissue on the development of multiple myeloma. Mol Biol Rep. 2025;52(1):74.","journal-title":"Mol Biol Rep"},{"key":"3741_CR20","doi-asserted-by":"crossref","unstructured":"Razavi ZS, Razavi FS, Alizadeh SS. Inorganic nanoparticles and Blood-Brain barrier modulation: advancing targeted neurological therapies. Eur J Med Chem, 2025: p. 117357.","DOI":"10.1016\/j.ejmech.2025.117357"},{"issue":"2","key":"3741_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2025.5718","volume":"66","author":"N He","year":"2025","unstructured":"He N, et al. LGR4 promotes proliferation and homing via activation of the NF\u2013\u03baB signaling pathway in multiple myeloma. Int J Oncol. 2025;66(2):1\u201316.","journal-title":"Int J Oncol"},{"issue":"1","key":"3741_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2967\/jnumed.124.267657","volume":"66","author":"SN dos Santos","year":"2025","unstructured":"dos Santos SN, Witney TH. Molecular imaging of cancer stem cells and their role in therapy resistance. J Nucl Med. 2025;66(1):14\u20139.","journal-title":"J Nucl Med"},{"key":"3741_CR23","doi-asserted-by":"publisher","first-page":"204062072413103","DOI":"10.1177\/20406207241310332","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, et al. Hematopoietic stem cell microtransplantation: current situation and challenges. Therapeutic Adv Hematol. 2025;16:20406207241310332.","journal-title":"Therapeutic Adv Hematol"},{"key":"3741_CR24","doi-asserted-by":"crossref","unstructured":"Akad F et al. Mesenchymal stem Cell-Derived exosomes modulate angiogenesis in gastric cancer. Biomedicines, 2023. 11(4).","DOI":"10.3390\/biomedicines11041031"},{"issue":"5","key":"3741_CR25","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s41375-021-01147-y","volume":"35","author":"A Carrasco-Leon","year":"2021","unstructured":"Carrasco-Leon A, et al. Characterization of complete LncRNAs transcriptome reveals the functional and clinical impact of LncRNAs in multiple myeloma. Leukemia. 2021;35(5):1438\u201350.","journal-title":"Leukemia"},{"key":"3741_CR26","doi-asserted-by":"crossref","unstructured":"Yarahmadi A et al. Mesenchymal stem cell and their extracellular vesicle therapy for neurological disorders: traumatic brain injury and beyond. Front Neurol. 16: p. 1472679.","DOI":"10.3389\/fneur.2025.1472679"},{"key":"3741_CR27","doi-asserted-by":"crossref","unstructured":"Sheikhi K et al. Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges. Front Cell Dev Biology 13: p. 1517369.","DOI":"10.3389\/fcell.2025.1517369"},{"issue":"1","key":"3741_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","volume":"7","author":"Y Han","year":"2022","unstructured":"Han Y, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Therapy. 2022;7(1):92.","journal-title":"Signal Transduct Target Therapy"},{"issue":"9","key":"3741_CR29","doi-asserted-by":"publisher","first-page":"e29858","DOI":"10.1016\/j.heliyon.2024.e29858","volume":"10","author":"SM Emami Meybodi","year":"2024","unstructured":"Emami Meybodi SM, Moradi Moraddahande F, Dehghani A, Firoozabadi. Immunogenic cell death mediated TLR3\/4-activated MSCs in U87 GBM cell line. Heliyon. 2024;10(9):e29858.","journal-title":"Heliyon"},{"issue":"10","key":"3741_CR30","doi-asserted-by":"publisher","first-page":"e22553","DOI":"10.1096\/fj.202101868RRR","volume":"36","author":"J Xu","year":"2022","unstructured":"Xu J, et al. Hypoxic bone marrow mesenchymal stromal cells-derived Exosomal miR-182-5p promotes liver regeneration via FOXO1-mediated macrophage polarization. Faseb J. 2022;36(10):e22553.","journal-title":"Faseb J"},{"key":"3741_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.biochi.2024.04.009","volume":"223","author":"HN Swain","year":"2024","unstructured":"Swain HN, et al. Mesenchymal stem cells in autoimmune disease: A systematic review and meta-analysis of pre-clinical studies. Biochimie. 2024;223:54\u201373.","journal-title":"Biochimie"},{"key":"3741_CR32","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","volume":"17","author":"TR Ullah","year":"2019","unstructured":"Ullah TR. The role of CXCR4 in multiple myeloma: cells\u2019 journey from bone marrow to beyond. J Bone Oncol. 2019;17:100253.","journal-title":"J Bone Oncol"},{"issue":"4","key":"3741_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/hematolrep16040070","volume":"16","author":"CA Mera Aza\u00edn","year":"2024","unstructured":"Mera Aza\u00edn CA, et al. Mesenchymal stem cells and reticulated platelets: new horizons in multiple myeloma. Hematol Rep. 2024;16(4):732\u201341.","journal-title":"Hematol Rep"},{"issue":"18","key":"3741_CR34","doi-asserted-by":"publisher","first-page":"10014","DOI":"10.3390\/ijms251810014","volume":"25","author":"F Abdelfattah","year":"2024","unstructured":"Abdelfattah F, et al. Omics studies of specialized cells and stem cells under microgravity conditions. Int J Mol Sci. 2024;25(18):10014.","journal-title":"Int J Mol Sci"},{"key":"3741_CR35","doi-asserted-by":"crossref","unstructured":"Xu S et al. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? 2018. 32(7): pp. 1500\u201314.","DOI":"10.1038\/s41375-018-0061-9"},{"key":"3741_CR36","doi-asserted-by":"crossref","unstructured":"Cippitelli M et al. Role of NF-\u03baB signaling in the interplay between multiple myeloma and mesenchymal stromal cells. 2023. 24(3): p. 1823.","DOI":"10.3390\/ijms24031823"},{"key":"3741_CR37","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-S\u00e1nchez D et al. Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression. 2023. 15(5): p. 421.","DOI":"10.4252\/wjsc.v15.i5.421"},{"key":"3741_CR38","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 T et al. Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells. 2015. 64: pp. 213\u201324.","DOI":"10.1007\/s00262-014-1623-y"},{"key":"3741_CR39","first-page":"1397005","volume":"15","author":"K Li","year":"2024","unstructured":"Li K, et al. Mesenchymal Stem cells-macrophages Crosstalk Myeloid Malignancy. 2024;15:1397005.","journal-title":"Mesenchymal Stem cells-macrophages Crosstalk Myeloid Malignancy"},{"key":"3741_CR40","doi-asserted-by":"crossref","unstructured":"Takam Kamga P et al. The role of Notch and Wnt signaling in MSC communication in normal and leukemic bone marrow niche. 2021. 8: p. 599276.","DOI":"10.3389\/fcell.2020.599276"},{"issue":"8","key":"3741_CR41","first-page":"879","volume":"37","author":"N Giuliani","year":"2009","unstructured":"Giuliani N, Mangoni M, Rizzoli VJEh. Osteogenic Differ Mesenchymal Stem Cells Multiple Myeloma: Identif Potential Therapeutic Targets. 2009;37(8):879\u201386.","journal-title":"Osteogenic Differ Mesenchymal Stem Cells Multiple Myeloma: Identif Potential Therapeutic Targets"},{"issue":"13","key":"3741_CR42","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast Inhibition. Blood. 2006;108(13):3992\u20136.","journal-title":"Blood"},{"issue":"1","key":"3741_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/nyas.12578","volume":"1335","author":"D Toscani","year":"2015","unstructured":"Toscani D, et al. The osteoblastic niche in the context of multiple myeloma. Ann N Y Acad Sci. 2015;1335(1):45\u201362.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"3741_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/er.2017-00064","volume":"38","author":"W-C Lee","year":"2017","unstructured":"Lee W-C, et al. Energy metabolism of the osteoblast: implications for osteoporosis. Endocr Rev. 2017;38(3):255\u201366.","journal-title":"Endocr Rev"},{"issue":"3","key":"3741_CR45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2009","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23(3):435\u201341.","journal-title":"Leukemia"},{"issue":"11","key":"3741_CR46","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.3390\/cancers12113267","volume":"12","author":"M Chiu","year":"2020","unstructured":"Chiu M, et al. Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability. Cancers. 2020;12(11):3267.","journal-title":"Cancers"},{"key":"3741_CR47","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/S2152-2650(22)00422-0","volume":"22","author":"D Toscani","year":"2022","unstructured":"Toscani D, et al. P-092: impaired Glutamine\/glutamate metabolic axis into myeloma microenvironment affects osteoclast formation. Clin Lymphoma Myeloma Leuk. 2022;22:S86.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"3741_CR48","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41574-019-0246-y","volume":"15","author":"N Dirckx","year":"2019","unstructured":"Dirckx N, et al. The role of osteoblasts in energy homeostasis. Nat Reviews Endocrinol. 2019;15(11):651\u201365.","journal-title":"Nat Reviews Endocrinol"},{"issue":"5","key":"3741_CR49","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.3390\/ijms24054893","volume":"24","author":"O Lungu","year":"2023","unstructured":"Lungu O, et al. The metabolic features of osteoblasts: implications for multiple myeloma (MM) bone disease. Int J Mol Sci. 2023;24(5):4893.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3741_CR50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metabol. 2022;34(3):355\u201377.","journal-title":"Cell Metabol"},{"key":"3741_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jconrel.2020.08.012","volume":"327","author":"FM Kashkooli","year":"2020","unstructured":"Kashkooli FM, Soltani M, Souri M. Controlled anti-cancer drug release through advanced nano-drug delivery systems: static and dynamic targeting strategies. J Controlled Release. 2020;327:316\u201349.","journal-title":"J Controlled Release"},{"key":"3741_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2021.11.024","volume":"341","author":"M Souri","year":"2022","unstructured":"Souri M, et al. Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles. J Controlled Release. 2022;341:227\u201346.","journal-title":"J Controlled Release"},{"issue":"5","key":"3741_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/iub.315","volume":"62","author":"R Augustin","year":"2010","unstructured":"Augustin R. The protein family of glucose transport facilitators: it\u2019s not only about glucose after all. IUBMB Life. 2010;62(5):315\u201333.","journal-title":"IUBMB Life"},{"issue":"11","key":"3741_CR54","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1210\/en.2016-1583","volume":"157","author":"Z Li","year":"2016","unstructured":"Li Z, et al. Glucose transporter-4 facilitates insulin-stimulated glucose uptake in osteoblasts. Endocrinology. 2016;157(11):4094\u2013103.","journal-title":"Endocrinology"},{"issue":"8","key":"3741_CR55","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.3390\/ijms22084120","volume":"22","author":"A Donat","year":"2021","unstructured":"Donat A, et al. Glucose metabolism in osteoblasts in healthy and pathophysiological conditions. Int J Mol Sci. 2021;22(8):4120.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3741_CR56","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cmet.2013.03.017","volume":"17","author":"E Esen","year":"2013","unstructured":"Esen E, et al. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation. Cell Metabol. 2013;17(5):745\u201355.","journal-title":"Cell Metabol"},{"issue":"5","key":"3741_CR57","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1210\/en.2013-1974","volume":"155","author":"AR Guntur","year":"2014","unstructured":"Guntur AR, et al. Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass. Endocrinology. 2014;155(5):1589\u201395.","journal-title":"Endocrinology"},{"issue":"5930","key":"3741_CR58","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u201333.","journal-title":"Science"},{"issue":"5","key":"3741_CR59","first-page":"1649","volume":"5","author":"H-R Demel","year":"2015","unstructured":"Demel H-R, et al. Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K\/Akt\/mTOR signaling in multiple myeloma cells. Am J cancer Res. 2015;5(5):1649.","journal-title":"Am J cancer Res"},{"issue":"7","key":"3741_CR60","first-page":"2145","volume":"10","author":"H Namikawa-Kanai","year":"2020","unstructured":"Namikawa-Kanai H, et al. Comparison of the amino acid profile between the nontumor and tumor regions in patients with lung cancer. Am J Cancer Res. 2020;10(7):2145.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"3741_CR61","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s12276-020-00504-8","volume":"52","author":"HC Yoo","year":"2020","unstructured":"Yoo HC, et al. Glutamine reliance in cell metabolism. Exp Mol Med. 2020;52(9):1496\u2013516.","journal-title":"Exp Mol Med"},{"issue":"1","key":"3741_CR62","first-page":"jcs251645","volume":"134","author":"L Shen","year":"2021","unstructured":"Shen L, et al. Biphasic regulation of glutamine consumption by WNT during osteoblast differentiation. J Cell Sci. 2021;134(1):jcs251645.","journal-title":"J Cell Sci"},{"issue":"1","key":"3741_CR63","first-page":"8928934","volume":"2019","author":"T Zhou","year":"2019","unstructured":"Zhou T, et al. Glutamine metabolism is essential for stemness of bone marrow mesenchymal stem cells and bone homeostasis. Stem Cells Int. 2019;2019(1):8928934.","journal-title":"Stem Cells Int"},{"key":"3741_CR64","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s00223-011-9537-6","volume":"89","author":"PM Brown","year":"2011","unstructured":"Brown PM, Hutchison JD, Crockett JC. Absence of glutamine supplementation prevents differentiation of murine calvarial osteoblasts to a mineralizing phenotype. Calcif Tissue Int. 2011;89:472\u201382.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"3741_CR65","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.cmet.2019.01.016","volume":"29","author":"Y Yu","year":"2019","unstructured":"Yu Y, et al. Glutamine metabolism regulates proliferation and lineage allocation in skeletal stem cells. Cell Metabol. 2019;29(4):966\u201378. e4.","journal-title":"Cell Metabol"},{"key":"3741_CR66","doi-asserted-by":"publisher","first-page":"1015402","DOI":"10.3389\/fonc.2022.1015402","volume":"12","author":"V Raimondi","year":"2022","unstructured":"Raimondi V, et al. Metabolic features of myeloma cells in the context of bone microenvironment: implication for the pathophysiology and clinic of myeloma bone disease. Front Oncol. 2022;12:1015402.","journal-title":"Front Oncol"},{"issue":"8","key":"3741_CR67","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3390\/cancers12082107","volume":"12","author":"R Hass","year":"2020","unstructured":"Hass R. Role of MSC in the tumor microenvironment. Cancers. 2020;12(8):2107.","journal-title":"Cancers"},{"key":"3741_CR68","doi-asserted-by":"publisher","first-page":"101057","DOI":"10.1016\/j.nantod.2020.101057","volume":"36","author":"FM Kashkooli","year":"2021","unstructured":"Kashkooli FM, et al. Nexus between in Silico and in vivo models to enhance clinical translation of nanomedicine. Nano Today. 2021;36:101057.","journal-title":"Nano Today"},{"key":"3741_CR69","doi-asserted-by":"publisher","first-page":"100208","DOI":"10.1016\/j.mtbio.2022.100208","volume":"13","author":"M Souri","year":"2022","unstructured":"Souri M, et al. Towards principled design of cancer nanomedicine to accelerate clinical translation. Mater Today Bio. 2022;13:100208.","journal-title":"Mater Today Bio"},{"issue":"8","key":"3741_CR70","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.burns.2023.01.005","volume":"49","author":"M Mirshekar","year":"2023","unstructured":"Mirshekar M, et al. Potential antibacterial activity and healing effect of topical administration of bone marrow and adipose mesenchymal stem cells encapsulated in collagen-fibrin hydrogel scaffold on full-thickness burn wound infection caused by Pseudomonas aeruginosa. Burns. 2023;49(8):1944\u201357.","journal-title":"Burns"},{"issue":"1","key":"3741_CR71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11033-024-10163-x","volume":"52","author":"S Teymouri","year":"2024","unstructured":"Teymouri S, et al. Beyond antibiotics: mesenchymal stem cells and bacteriophages-new approaches to combat bacterial resistance in wound infections. Mol Biol Rep. 2024;52(1):64.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"3741_CR72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/path.5357","volume":"250","author":"S Galland","year":"2020","unstructured":"Galland S, Stamenkovic I. Mesenchymal stromal cells in cancer: a review of their Immunomodulatory functions and dual effects on tumor progression. J Pathol. 2020;250(5):555\u201372.","journal-title":"J Pathol"},{"issue":"1","key":"3741_CR73","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1038\/s41598-024-58886-y","volume":"14","author":"M EskandariNasab","year":"2024","unstructured":"EskandariNasab M, et al. A GRU\u2013CNN model for auditory attention detection using microstate and recurrence quantification analysis. Sci Rep. 2024;14(1):8861.","journal-title":"Sci Rep"},{"issue":"7","key":"3741_CR74","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/cells10071729","volume":"10","author":"R Guillamat-Prats","year":"2021","unstructured":"Guillamat-Prats R. The role of MSC in wound healing, scarring and regeneration. Cells. 2021;10(7):1729.","journal-title":"Cells"},{"issue":"1","key":"3741_CR75","doi-asserted-by":"publisher","first-page":"19350","DOI":"10.1038\/s41598-021-98638-w","volume":"11","author":"M Soltani","year":"2021","unstructured":"Soltani M, Souri M, Moradi F, Kashkooli. Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors. Sci Rep. 2021;11(1):19350.","journal-title":"Sci Rep"},{"issue":"10","key":"3741_CR76","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.3390\/cancers13102481","volume":"13","author":"M Soltani","year":"2021","unstructured":"Soltani M, et al. Enhancing clinical translation of cancer using nanoinformatics. Cancers. 2021;13(10):2481.","journal-title":"Cancers"},{"issue":"17","key":"3741_CR77","doi-asserted-by":"publisher","first-page":"13511","DOI":"10.3390\/ijms241713511","volume":"24","author":"Y Slama","year":"2023","unstructured":"Slama Y, et al. The dual role of mesenchymal stem cells in cancer pathophysiology: pro-tumorigenic effects versus therapeutic potential. Int J Mol Sci. 2023;24(17):13511.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3741_CR78","doi-asserted-by":"publisher","first-page":"e12712","DOI":"10.1111\/cpr.12712","volume":"53","author":"W Jiang","year":"2020","unstructured":"Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1):e12712.","journal-title":"Cell Prolif"},{"issue":"22","key":"3741_CR79","doi-asserted-by":"publisher","first-page":"12429","DOI":"10.3390\/ijms222212429","volume":"22","author":"CR Harrell","year":"2021","unstructured":"Harrell CR, et al. Mesenchymal stem cell: a friend or foe in anti-tumor immunity. Int J Mol Sci. 2021;22(22):12429.","journal-title":"Int J Mol Sci"},{"key":"3741_CR80","doi-asserted-by":"publisher","first-page":"624746","DOI":"10.3389\/fimmu.2021.624746","volume":"12","author":"N Luque-Campos","year":"2021","unstructured":"Luque-Campos N, et al. The macrophage response is driven by mesenchymal stem Cell-Mediated metabolic reprogramming. Front Immunol. 2021;12:624746.","journal-title":"Front Immunol"},{"issue":"1","key":"3741_CR81","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13287-023-03381-w","volume":"14","author":"M Peshkova","year":"2023","unstructured":"Peshkova M, et al. MSCs\u2019 conditioned media cytokine and growth factor profiles and their impact on macrophage polarization. Stem Cell Res Ther. 2023;14(1):142.","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"3741_CR82","first-page":"653","volume":"41","author":"N Song","year":"2020","unstructured":"Song N, Scholtemeijer M, Shah K. Mesenchymal Stem Cell Immunomodulation: Mech Therapeutic Potential Trends Pharmacol Sci. 2020;41(9):653\u201364.","journal-title":"Mesenchymal Stem Cell Immunomodulation: Mech Therapeutic Potential Trends Pharmacol Sci"},{"issue":"2","key":"3741_CR83","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/rheumatology\/keaa745","volume":"60","author":"M Alahdal","year":"2021","unstructured":"Alahdal M, et al. Potential efficacy of dendritic cell Immunomodulation in the treatment of osteoarthritis. Rheumatology. 2021;60(2):507\u201317.","journal-title":"Rheumatology"},{"issue":"3","key":"3741_CR84","doi-asserted-by":"publisher","first-page":"e0213170","DOI":"10.1371\/journal.pone.0213170","volume":"14","author":"AG Laing","year":"2019","unstructured":"Laing AG, et al. Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress. PLoS ONE. 2019;14(3):e0213170.","journal-title":"PLoS ONE"},{"issue":"1","key":"3741_CR85","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13287-019-1307-9","volume":"10","author":"P Luz-Crawford","year":"2019","unstructured":"Luz-Crawford P, et al. Mesenchymal stem cell repression of Th17 cells is triggered by mitochondrial transfer. Stem Cell Res Ther. 2019;10(1):232.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"3741_CR86","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/stem.3151","volume":"38","author":"N Negi","year":"2020","unstructured":"Negi N, Griffin MD. Effects of mesenchymal stromal cells on regulatory T cells: current Understanding and clinical relevance. Stem Cells. 2020;38(5):596\u2013605.","journal-title":"Stem Cells"},{"issue":"12","key":"3741_CR87","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/stmcls\/sxac064","volume":"40","author":"AP Porter","year":"2022","unstructured":"Porter AP, et al. Conglomeration of T-and B-cell matrix responses determines the potency of human bone marrow mesenchymal stromal cells. Stem Cells. 2022;40(12):1134\u201348.","journal-title":"Stem Cells"},{"issue":"6","key":"3741_CR88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/intimm\/dxy018","volume":"30","author":"A Kayaba","year":"2018","unstructured":"Kayaba A, et al. Bone marrow PDGFR\u03b1\u2009+\u2009Sca-1+-enriched mesenchymal stem cells support survival of and antibody production by plasma cells in vitro through IL-6. Int Immunol. 2018;30(6):241\u201353.","journal-title":"Int Immunol"},{"key":"3741_CR89","doi-asserted-by":"crossref","unstructured":"Nguyen DC et al. Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion (vol 9, 3698, 2018). NATURE COMMUNICATIONS, 2019. 10.","DOI":"10.1038\/s41467-019-08400-0"},{"issue":"9","key":"3741_CR90","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3324\/haematol.12857","volume":"93","author":"S Tabera","year":"2008","unstructured":"Tabera S, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica. 2008;93(9):1301\u20139.","journal-title":"Haematologica"},{"key":"3741_CR91","doi-asserted-by":"publisher","first-page":"106954","DOI":"10.1016\/j.phrs.2023.106954","volume":"197","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Efficacy and safety of Gutong patch compared with NSAIDs for knee osteoarthritis: A real-world multicenter, prospective cohort study in China. Pharmacol Res. 2023;197:106954.","journal-title":"Pharmacol Res"},{"issue":"1","key":"3741_CR92","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12951-024-02533-1","volume":"22","author":"G Yu","year":"2024","unstructured":"Yu G, et al. Evaluating the pro-survival potential of apoptotic bodies derived from 2D- and 3D- cultured adipose stem cells in ischaemic flaps. J Nanobiotechnol. 2024;22(1):333.","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"3741_CR93","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/ddr.22051","volume":"84","author":"J Zhu","year":"2023","unstructured":"Zhu J, et al. Combination of chemotherapy and gaseous signaling molecular therapy: novel \u03b2-elemene nitric oxide donor derivatives against leukemia. Drug Dev Res. 2023;84(4):718\u201335.","journal-title":"Drug Dev Res"},{"key":"3741_CR94","doi-asserted-by":"publisher","first-page":"111408","DOI":"10.1016\/j.matdes.2022.111408","volume":"224","author":"X Huang","year":"2022","unstructured":"Huang X, et al. Study on craniocerebral dynamics response and helmet protective performance under the blast waves. Mater Design. 2022;224:111408.","journal-title":"Mater Design"},{"key":"3741_CR95","doi-asserted-by":"crossref","unstructured":"Li YY, et al. ScImmOmics: a manually curated resource of single-cell multi-omics immune data. Nucleic Acids Res; 2024.","DOI":"10.1093\/nar\/gkae985"},{"issue":"7","key":"3741_CR96","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.stem.2024.04.021","volume":"31","author":"S Li","year":"2024","unstructured":"Li S, et al. Modified lentiviral globin gene therapy for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia: A single-center, single-arm pilot trial. Cell Stem Cell. 2024;31(7):961\u2013e9738.","journal-title":"Cell Stem Cell"},{"key":"3741_CR97","doi-asserted-by":"publisher","first-page":"110525","DOI":"10.1016\/j.biopha.2020.110525","volume":"130","author":"A Xu","year":"2020","unstructured":"Xu A, et al. NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2020;130:110525.","journal-title":"Biomed Pharmacother"},{"key":"3741_CR98","doi-asserted-by":"crossref","unstructured":"Razavi ZS et al. Stem cells and bio scaffolds for the treatment of cardiovascular diseases: new insights. Front Cell Dev Biology, 2024. 12.","DOI":"10.3389\/fcell.2024.1472103"},{"key":"3741_CR99","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-8722-7-14","volume":"7","author":"Z Sun","year":"2014","unstructured":"Sun Z, Wang S, Zhao RC. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol. 2014;7:14.","journal-title":"J Hematol Oncol"},{"key":"3741_CR100","doi-asserted-by":"crossref","unstructured":"Hideshima T, Anderson KC. Signal Pathw Mediating Myeloma Cell Growth Survival Cancers (Basel), 2021. 13(2).","DOI":"10.3390\/cancers13020216"},{"issue":"11","key":"3741_CR101","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/cancers13112542","volume":"13","author":"P Maiso","year":"2021","unstructured":"Maiso P, et al. Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression. Cancers. 2021;13(11):2542.","journal-title":"Cancers"},{"issue":"8","key":"3741_CR102","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima T, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585\u201398.","journal-title":"Nat Rev Cancer"},{"key":"3741_CR103","doi-asserted-by":"crossref","unstructured":"Razavi Z et al. CRISPR-Driven Biosensors: A New Frontier in Rapid and Accurate Disease Detection. Critical Reviews in Analytical Chemistry: pp. 1\u201325.","DOI":"10.1080\/10408347.2024.2400267"},{"key":"3741_CR104","doi-asserted-by":"crossref","unstructured":"Cippitelli M et al. Role of NF-\u03baB signaling in the interplay between multiple myeloma and mesenchymal stromal cells. Int J Mol Sci, 2023. 24(3).","DOI":"10.3390\/ijms24031823"},{"issue":"4","key":"3741_CR105","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00418-018-1643-3","volume":"149","author":"H Liu","year":"2018","unstructured":"Liu H, et al. Inflammation, mesenchymal stem cells and bone regeneration. Histochem Cell Biol. 2018;149(4):393\u2013404.","journal-title":"Histochem Cell Biol"},{"key":"3741_CR106","doi-asserted-by":"crossref","unstructured":"Razavi Z, et al. Microfluidic systems for modeling digestive cancer: a review of recent progress. Biomedical Physics & Engineering Ex; 2024.","DOI":"10.1088\/2057-1976\/ad6f15"},{"key":"3741_CR107","doi-asserted-by":"crossref","unstructured":"Hofbauer D et al. \u03b2(2)-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. Immunity, 2021. 54(8): pp. 1772\u20131787.e9.","DOI":"10.1016\/j.immuni.2021.07.002"},{"issue":"10","key":"3741_CR108","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3889\/oamjms.2018.404","volume":"6","author":"A Putra","year":"2018","unstructured":"Putra A, et al. The role of TNF-\u03b1 induced MSCs on suppressive inflammation by increasing TGF-\u03b2 and IL-10. Open Access Maced J Med Sci. 2018;6(10):1779\u201383.","journal-title":"Open Access Maced J Med Sci"},{"issue":"8","key":"3741_CR109","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.exphem.2009.04.004","volume":"37","author":"N Giuliani","year":"2009","unstructured":"Giuliani N, Mangoni M, Rizzoli V. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol. 2009;37(8):879\u201386.","journal-title":"Exp Hematol"},{"issue":"7\u20138","key":"3741_CR110","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2119\/molmed.2010.00157","volume":"17","author":"K Suzuki","year":"2011","unstructured":"Suzuki K, et al. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med. 2011;17(7\u20138):579\u201387.","journal-title":"Mol Med"},{"issue":"5","key":"3741_CR111","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/scrt322","volume":"4","author":"I Atsuta","year":"2013","unstructured":"Atsuta I, et al. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas\/Fas ligand pathway. Stem Cell Res Ther. 2013;4(5):111.","journal-title":"Stem Cell Res Ther"},{"key":"3741_CR112","doi-asserted-by":"crossref","unstructured":"Herv\u00e1s-Salcedo R, Mart\u00edn-Antonio B. A journey through the Inter-Cellular interactions in the bone marrow in multiple myeloma: implications for the next generation of treatments. Cancers (Basel), 2022. 14(15).","DOI":"10.3390\/cancers14153796"},{"key":"3741_CR113","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.biopha.2017.08.120","volume":"95","author":"M Hu","year":"2017","unstructured":"Hu M, et al. IL-1\u03b2-induced NF-\u03baB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1. Biomed Pharmacother. 2017;95:1147\u201355.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3741_CR114","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00586-014-3527-0","volume":"24","author":"M Domenicucci","year":"2015","unstructured":"Domenicucci M, et al. Post-traumatic Collet-Sicard syndrome: personal observation and review of the pertinent literature with clinical, radiologic and anatomic considerations. Eur Spine J. 2015;24(4):663\u201370.","journal-title":"Eur Spine J"},{"issue":"Pt 6","key":"3741_CR115","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/brain\/awq014","volume":"133","author":"P Missori","year":"2010","unstructured":"Missori P, Paolini S, Curr\u00e0 A. From congenital to idiopathic adult hydrocephalus: a historical research. Brain. 2010;133(Pt 6):1836\u201349.","journal-title":"Brain"},{"issue":"1","key":"3741_CR116","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13287-021-02690-2","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, et al. Immunomodulatory effects of mesenchymal stem cells in peripheral nerve injury. Stem Cell Res Ther. 2022;13(1):18.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"3741_CR117","doi-asserted-by":"publisher","first-page":"e0151629","DOI":"10.1371\/journal.pone.0151629","volume":"11","author":"S Rinalduzzi","year":"2016","unstructured":"Rinalduzzi S, et al. Stance postural strategies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE. 2016;11(3):e0151629.","journal-title":"PLoS ONE"},{"issue":"1","key":"3741_CR118","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13287-022-02777-4","volume":"13","author":"B Abbasi","year":"2022","unstructured":"Abbasi B, et al. Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications. Stem Cell Res Ther. 2022;13(1):97.","journal-title":"Stem Cell Res Ther"},{"key":"3741_CR119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fneur.2015.00015","volume":"6","author":"P Missori","year":"2015","unstructured":"Missori P, Curr\u00e0 A. Progressive cognitive impairment evolving to dementia parallels parieto-occipital and Temporal enlargement in idiopathic chronic hydrocephalus: a retrospective cohort study. Front Neurol. 2015;6:15.","journal-title":"Front Neurol"},{"key":"3741_CR120","doi-asserted-by":"crossref","unstructured":"Trigo CM, et al. Mesenchymal stem cell secretome for regenerative medicine: where do we stand? Journal of Advanced Research; 2024.","DOI":"10.1016\/j.jare.2024.05.004"},{"issue":"A","key":"3741_CR121","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3889\/oamjms.2021.6434","volume":"9","author":"S Bazarbaeva","year":"2021","unstructured":"Bazarbaeva S, et al. Morphofunctional and hematological characteristics of health in students from the Northern and Southern regions of Kazakhstan. Open Access Macedonian J Med Sci. 2021;9(A):753\u20139.","journal-title":"Open Access Macedonian J Med Sci"},{"issue":"18","key":"3741_CR122","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3390\/cells13181556","volume":"13","author":"S Dadfar","year":"2024","unstructured":"Dadfar S, et al. The role of mesenchymal stem cells in modulating adaptive immune responses in multiple sclerosis. Cells. 2024;13(18):1556.","journal-title":"Cells"},{"issue":"3","key":"3741_CR123","first-page":"130521","volume":"15","author":"AS Dinmukhamedova","year":"2021","unstructured":"Dinmukhamedova AS, et al. Morphofunctional, hematological and biochemical indicators of First-Year students who came to study from urban and rural areas. Clin Schizophrenia Relat Psychoses. 2021;15(3):130521\u2013130521.","journal-title":"Clin Schizophrenia Relat Psychoses"},{"key":"3741_CR124","doi-asserted-by":"crossref","unstructured":"Zhou Y et al. The role of mesenchymal stem cells derived exosomes as a novel nanobiotechnology target in the diagnosis and treatment of cancer. Front Bioeng Biotechnol, 2023. 11.","DOI":"10.3389\/fbioe.2023.1214190"},{"key":"3741_CR125","unstructured":"Mukataeva Z et al. The main trends in morpho-functional development of Kazakh schoolchildren. 2020."},{"key":"3741_CR126","doi-asserted-by":"crossref","unstructured":"Mukataeva ZM, Dinmukhamedova AS, Aizman RI. Comparative analysis of schoolchildren\u2019s morpho-functional development as the basis for health monitoring (with the main focus on northern and southern Kazakhstan regions). 2019.","DOI":"10.15293\/2658-6762.1905.08"},{"issue":"8","key":"3741_CR127","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.5966\/sctm.2015-0331","volume":"5","author":"D Ali","year":"2016","unstructured":"Ali D, et al. Epigenetic library screen identifies abexinostat as novel regulator of adipocytic and osteoblastic differentiation of human skeletal (Mesenchymal) stem cells. Stem Cells Transl Med. 2016;5(8):1036\u201347.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"3741_CR128","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cell.2004.10.024","volume":"119","author":"RB Vega","year":"2004","unstructured":"Vega RB, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell. 2004;119(4):555\u201366.","journal-title":"Cell"},{"issue":"440","key":"3741_CR129","doi-asserted-by":"publisher","first-page":"ra79","DOI":"10.1126\/scisignal.aaf3273","volume":"9","author":"LR Carpio","year":"2016","unstructured":"Carpio LR, et al. Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling. Sci Signal. 2016;9(440):ra79.","journal-title":"Sci Signal"},{"issue":"7","key":"3741_CR130","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383(7):650\u201363.","journal-title":"N Engl J Med"},{"key":"3741_CR131","doi-asserted-by":"crossref","unstructured":"Wang R et al. Epigenetic Regulation in Mesenchymal Stem Cell Aging and Differentiation and Osteoporosis. Stem Cells International, 2020. 2020: p. 8836258.","DOI":"10.1155\/2020\/8836258"},{"key":"3741_CR132","doi-asserted-by":"crossref","unstructured":"Bure IV, Nemtsova MV, Kuznetsova EB. Histone modifications and Non-Coding RNAs: mutual epigenetic regulation and role in pathogenesis. Int J Mol Sci, 2022. 23(10).","DOI":"10.3390\/ijms23105801"},{"key":"3741_CR133","doi-asserted-by":"crossref","unstructured":"Razavi Z et al. CRISPR-microfluidics nexus: advancing biomedical applications for Understanding and detection. Sens Actuators A: Phys, 2024: p. 115625.","DOI":"10.1016\/j.sna.2024.115625"},{"issue":"4","key":"3741_CR134","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5045\/br.2022.2022097","volume":"57","author":"FC Tuncel","year":"2022","unstructured":"Tuncel FC, et al. Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma. Blood Res. 2022;57(4):250\u20135.","journal-title":"Blood Res"},{"key":"3741_CR135","doi-asserted-by":"crossref","unstructured":"Tsiouplis NJ et al. TET-Mediated epigenetic regulation in immune cell development and disease. Front Cell Dev Biology, 2021. 8.","DOI":"10.3389\/fcell.2020.623948"},{"issue":"4","key":"3741_CR136","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","volume":"15","author":"J Adamik","year":"2017","unstructured":"Adamik J, et al. EZH2 or HDAC1 Inhibition reverses multiple Myeloma-Induced epigenetic suppression of osteoblast differentiation. Mol Cancer Res. 2017;15(4):405\u201317.","journal-title":"Mol Cancer Res"},{"key":"3741_CR137","unstructured":"Otaghvar H et al. A brief report on the effect of COVID 19 pandemic on patients undergoing skin graft surgery in a burns hospital from March 2019 to March 2020. J Case Rep Med Hist, 2022. 2(8)."},{"issue":"1","key":"3741_CR138","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41467-020-20715-x","volume":"12","author":"A Garcia-Gomez","year":"2021","unstructured":"Garcia-Gomez A, et al. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Nat Commun. 2021;12(1):421.","journal-title":"Nat Commun"},{"issue":"2","key":"3741_CR139","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","volume":"117","author":"BA Walker","year":"2011","unstructured":"Walker BA, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117(2):553\u201362.","journal-title":"Blood"},{"issue":"4","key":"3741_CR140","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1101\/gr.180240.114","volume":"25","author":"X Agirre","year":"2015","unstructured":"Agirre X, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 2015;25(4):478\u201387.","journal-title":"Genome Res"},{"key":"3741_CR141","doi-asserted-by":"publisher","first-page":"8238496","DOI":"10.1155\/2018\/8238496","volume":"2018","author":"Y Cao","year":"2018","unstructured":"Cao Y, et al. Genome-Wide DNA methylation analysis during osteogenic differentiation of human bone marrow mesenchymal stem cells. Stem Cells Int. 2018;2018:8238496.","journal-title":"Stem Cells Int"},{"key":"3741_CR142","doi-asserted-by":"crossref","unstructured":"Ismail NH et al. The role of epigenetics in the development and progression of multiple myeloma. Biomedicines, 2022. 10(11).","DOI":"10.3390\/biomedicines10112767"},{"key":"3741_CR143","doi-asserted-by":"crossref","unstructured":"Allegra A et al. Epigenetic crosstalk between malignant plasma cells and the tumour microenvironment in multiple myeloma. Cancers (Basel), 2022. 14(11).","DOI":"10.3390\/cancers14112597"},{"issue":"1","key":"3741_CR144","doi-asserted-by":"publisher","first-page":"19539","DOI":"10.1038\/s41598-021-98554-z","volume":"11","author":"M Souri","year":"2021","unstructured":"Souri M, Soltani M, Moradi F, Kashkooli. Computational modeling of thermal combination therapies by magneto-ultrasonic heating to enhance drug delivery to solid tumors. Sci Rep. 2021;11(1):19539.","journal-title":"Sci Rep"},{"issue":"4","key":"3741_CR145","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11095-022-03255-5","volume":"39","author":"M Souri","year":"2022","unstructured":"Souri M, Moradi Kashkooli F, Soltani M. Analysis of magneto-hyperthermia duration in nano-sized drug delivery system to solid tumors using intravascular-triggered thermosensitive-liposome. Pharm Res. 2022;39(4):753\u201365.","journal-title":"Pharm Res"},{"issue":"5","key":"3741_CR146","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2174\/2211738511666230501202946","volume":"11","author":"H Abdollahzadeh","year":"2023","unstructured":"Abdollahzadeh H, et al. Liposomal doxorubicin kinetic study in an in vitro 2D and 3D tumor model for osteosarcoma in a perfusion bioreactor. Pharm Nanotechnol. 2023;11(5):447\u201359.","journal-title":"Pharm Nanotechnol"},{"issue":"3","key":"3741_CR147","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41580-018-0081-3","volume":"20","author":"T Narita","year":"2019","unstructured":"Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20(3):156\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"08","key":"3741_CR148","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3855\/jidc.17655","volume":"17","author":"A Rajaei","year":"2023","unstructured":"Rajaei A, et al. Activation of the DNA damage response pathway in the infected gastric tissue with Helicobacter pylori: a case-control study. J Infect Developing Ctries. 2023;17(08):1125\u20139.","journal-title":"J Infect Developing Ctries"},{"key":"3741_CR149","doi-asserted-by":"crossref","unstructured":"Pal D et al. Potential of synthetic and natural compounds as novel histone deacetylase inhibitors for the treatment of hematological malignancies. Cancers (Basel), 2023. 15(10).","DOI":"10.3390\/cancers15102808"},{"key":"3741_CR150","unstructured":"Molaei A et al. Pharmacological and Medical Effect of Modified Skin Grafting Method in Patients with Chronic and Severe Neck Burns. 2022."},{"issue":"5","key":"3741_CR151","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/aps.2012.182","volume":"34","author":"S Xu","year":"2013","unstructured":"Xu S, et al. Effect of the HDAC inhibitor Vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol Sin. 2013;34(5):699\u2013709.","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"3741_CR152","first-page":"3605","volume":"17","author":"M Ahmadvand","year":"2016","unstructured":"Ahmadvand M, et al. Comparison of expression signature of histone deacetylases (HDACs) in mesenchymal stem cells from multiple myeloma and normal donors. Asian Pac J Cancer Prev. 2016;17(7):3605\u201310.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"3741_CR153","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00277-017-2980-3","volume":"96","author":"M Baljevic","year":"2017","unstructured":"Baljevic M, et al. Phase II study of the c-MET inhibitor Tivantinib (ARQ 197) in patients with relapsed or relapsed\/refractory multiple myeloma. Ann Hematol. 2017;96(6):977\u201385.","journal-title":"Ann Hematol"},{"issue":"7","key":"3741_CR154","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nbt0714-607b","volume":"32","author":"A Mullard","year":"2014","unstructured":"Mullard A. Green light for Janssen\u2019s IL-6 blocker. Nat Biotechnol. 2014;32(7):607.","journal-title":"Nat Biotechnol"},{"issue":"25","key":"3741_CR155","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1182\/blood-2011-07-368142","volume":"120","author":"S Blotta","year":"2012","unstructured":"Blotta S, et al. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012;120(25):5002\u201313.","journal-title":"Blood"},{"issue":"2","key":"3741_CR156","doi-asserted-by":"publisher","first-page":"Ijh39","DOI":"10.2217\/ijh-2021-0017","volume":"11","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan M, et al. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. Int J Hematol Oncol. 2022;11(2):Ijh39.","journal-title":"Int J Hematol Oncol"},{"issue":"14","key":"3741_CR157","doi-asserted-by":"publisher","first-page":"10080","DOI":"10.1021\/acs.jmedchem.3c00977","volume":"66","author":"F Liu","year":"2023","unstructured":"Liu F, et al. Discovery of the first irreversible HDAC6 isoform selective inhibitor with potent Anti-Multiple myeloma activity. J Med Chem. 2023;66(14):10080\u201391.","journal-title":"J Med Chem"},{"issue":"5","key":"3741_CR158","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/17474086.2020.1744432","volume":"13","author":"A Oriol","year":"2020","unstructured":"Oriol A. A critical evaluation of pembrolizumab in addition to Lenalidomide and dexamethasone for the treatment of multiple myeloma. Expert Rev Hematol. 2020;13(5):435\u201345.","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"3741_CR159","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","volume":"30","author":"B Le Calvez","year":"2021","unstructured":"Le Calvez B, Moreau P, Touzeau C. Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. Expert Opin Investig Drugs. 2021;30(9):965\u201373.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"3741_CR160","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1038\/s41467-024-51442-2","volume":"15","author":"E Malek","year":"2024","unstructured":"Malek E, et al. The TGF\u03b2 type I receptor kinase inhibitor vactosertib in combination with Pomalidomide in relapsed\/refractory multiple myeloma: a phase 1b trial. Nat Commun. 2024;15(1):7388.","journal-title":"Nat Commun"},{"issue":"2","key":"3741_CR161","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1158\/1078-0432.CCR-19-0647","volume":"26","author":"IM Ghobrial","year":"2020","unstructured":"Ghobrial IM, et al. A phase Ib\/II trial of the First-in-Class Anti-CXCR4 antibody ulocuplumab in combination with Lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma. Clin Cancer Res. 2020;26(2):344\u201353.","journal-title":"Clin Cancer Res"},{"key":"3741_CR162","doi-asserted-by":"crossref","unstructured":"Ismail NH et al. Dysregulation of Non-Coding RNAs: roles of MiRNAs and LncRNAs in the pathogenesis of multiple myeloma. Noncoding RNA, 2023. 9(6).","DOI":"10.3390\/ncrna9060068"},{"key":"3741_CR163","doi-asserted-by":"crossref","unstructured":"Raimondi L et al. Non-Coding RNAs in multiple myeloma bone disease pathophysiology. Noncoding RNA, 2020. 6(3).","DOI":"10.3390\/ncrna6030037"},{"key":"3741_CR164","doi-asserted-by":"publisher","first-page":"1158484","DOI":"10.3389\/fbioe.2023.1158484","volume":"11","author":"G Mahmoudvand","year":"2023","unstructured":"Mahmoudvand G, et al. Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: new insight. Front Bioeng Biotechnol. 2023;11:1158484.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"3741_CR165","doi-asserted-by":"publisher","first-page":"2186312","DOI":"10.1080\/10717544.2023.2186312","volume":"30","author":"M Souri","year":"2023","unstructured":"Souri M, et al. Stimuli-sensitive nano-drug delivery with programmable size changes to enhance accumulation of therapeutic agents in tumors. Drug Delivery. 2023;30(1):2186312.","journal-title":"Drug Delivery"},{"issue":"1","key":"3741_CR166","doi-asserted-by":"publisher","first-page":"2219871","DOI":"10.1080\/10717544.2023.2219871","volume":"30","author":"F Moradi Kashkooli","year":"2023","unstructured":"Moradi Kashkooli F, et al. A Spatiotemporal computational model of focused ultrasound heat-induced nano-sized drug delivery system in solid tumors. Drug Delivery. 2023;30(1):2219871.","journal-title":"Drug Delivery"},{"issue":"3","key":"3741_CR167","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10238-015-0355-4","volume":"16","author":"X Shen","year":"2016","unstructured":"Shen X, et al. miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor. Clin Exp Med. 2016;16(3):307\u201316.","journal-title":"Clin Exp Med"},{"key":"3741_CR168","doi-asserted-by":"crossref","unstructured":"Karimi Rouzbahani A et al. Comparison of breastlight and mammography in women aged over 40 based on diagnostic accuracy. J Obstet Gynecol Cancer Res, 2024: pp. 2\u20132.","DOI":"10.30699\/jogcr.9.6.621"},{"issue":"1","key":"3741_CR169","doi-asserted-by":"publisher","first-page":"23363","DOI":"10.1038\/s41598-024-74138-5","volume":"14","author":"M Amirnorouzi","year":"2024","unstructured":"Amirnorouzi M, et al. Negative feedback loop in the activation of non-homologous end joining DNA repair pathway in Helicobacter pylori infected patients with gastritis. Sci Rep. 2024;14(1):23363.","journal-title":"Sci Rep"},{"issue":"8","key":"3741_CR170","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","volume":"19","author":"E Leone","year":"2013","unstructured":"Leone E, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013;19(8):2096\u2013106.","journal-title":"Clin Cancer Res"},{"key":"3741_CR171","unstructured":"Sarkulova Z et al. [THE LEVEL OF S100\u0392 IN BLOOD SERUM AS A PROGNOSTIC FACTOR OF OUTCOME IN SECONDARY BRAIN LESIONS]. Georgian Med News, 2021(321): pp. 162\u20138."},{"key":"3741_CR172","doi-asserted-by":"crossref","unstructured":"Liu R et al. Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. MedComm (2020), 2023. 4(3): p. e292.","DOI":"10.1002\/mco2.292"},{"key":"3741_CR173","doi-asserted-by":"crossref","unstructured":"Kazempour A, Balogh P. Margination behavior of a Circulating cell in a tortuous microvessel. Phys Fluids, 2024. 36(9).","DOI":"10.1063\/5.0227716"},{"issue":"1","key":"3741_CR174","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12063-023-00423-7","volume":"17","author":"J Valizadeh","year":"2024","unstructured":"Valizadeh J, et al. An operational planning for emergency medical services considering the application of IoT. Oper Manage Res. 2024;17(1):267\u201390.","journal-title":"Oper Manage Res"},{"key":"3741_CR175","first-page":"139","volume":"343","author":"Z Sarkulova","year":"2023","unstructured":"Sarkulova Z, et al. FACTORS OF AGGRESSION AT THE STAGES OF OPEN SURGICAL TREATMENT OF SEVERE FORMS OF PERITONITIS. Georgian Med News. 2023;343:139\u201343.","journal-title":"Georgian Med News"},{"key":"3741_CR176","doi-asserted-by":"publisher","first-page":"107410","DOI":"10.1016\/j.phrs.2024.107410","volume":"208","author":"L-Y Zhang","year":"2024","unstructured":"Zhang L-Y, et al. Role of histone deacetylases and their inhibitors in neurological diseases. Pharmacol Res. 2024;208:107410.","journal-title":"Pharmacol Res"},{"key":"3741_CR177","unstructured":"Khaniki MAL, Mirzaeibonehkhater M, Manthouri M. Enhancing Pneumonia Detection using Vision Transformer with Dynamic Mapping Re-Attention Mechanism. in 2023 13th International Conference on Computer and Knowledge Engineering (ICCKE). 2023."},{"issue":"2","key":"3741_CR178","doi-asserted-by":"publisher","first-page":"zqae004","DOI":"10.1093\/function\/zqae004","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Epigenetic regulation of autophagy in bone metabolism. Function (Oxf). 2024;5(2):zqae004.","journal-title":"Function (Oxf)"},{"key":"3741_CR179","doi-asserted-by":"crossref","unstructured":"Bolhassani M, Oksuz I. Semi-Supervised Segmentation of Multi-vendor and Multi-center Cardiac MRI. in 2021 29th Signal Processing and Communications Applications Conference (SIU). 2021.","DOI":"10.1109\/SIU53274.2021.9477818"},{"issue":"14","key":"3741_CR180","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/cells13141209","volume":"13","author":"C Cristalli","year":"2024","unstructured":"Cristalli C, Scotlandi K. Targeting DNA methylation machinery in pediatric solid tumors. Cells. 2024;13(14):1209.","journal-title":"Cells"},{"issue":"5","key":"3741_CR181","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.15419\/bmrat.v5i5.443","volume":"5","author":"FR Sharbaf","year":"2018","unstructured":"Sharbaf FR, et al. Comparison of fetal middle cerebral artery versus umbilical artery color doppler ultrasound for predicting neonatal outcome in complicated pregnancies with fetal growth restriction. Biomedical Res Therapy. 2018;5(5):2296\u2013304.","journal-title":"Biomedical Res Therapy"},{"key":"3741_CR182","doi-asserted-by":"crossref","unstructured":"Gao Y et al. Immune checkpoint inhibitors (anti PD-1 or anti PD\u2010L1) plus platinum\u2010etoposide versus platinum\u2010etoposide alone for first\u2010line treatment of extensive small cell lung cancer. Cochrane Database Syst Rev, 2021. 2021(10).","DOI":"10.1002\/14651858.CD014809"},{"key":"3741_CR183","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. Regul Cancer Immune Checkpoints: Mol Cell Mech Therapy, 2020: pp. 201\u201326.","DOI":"10.1007\/978-981-15-3266-5_9"},{"key":"3741_CR184","unstructured":"Shen Y. Explainable artificial intelligence to stratify pan-cancer patients for immune checkpoint inhibitor decision making. University of Missouri\u2013Columbia; 2022."},{"issue":"10","key":"3741_CR185","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.3390\/ijms25105490","volume":"25","author":"J Qiu","year":"2024","unstructured":"Qiu J, et al. Immunomodulatory precision: A narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment. Int J Mol Sci. 2024;25(10):5490.","journal-title":"Int J Mol Sci"},{"key":"3741_CR186","doi-asserted-by":"crossref","unstructured":"Souri M, Soltani M. Clinical translation of gold nanoparticles: Obstacles and perspectives, in Gold nanoparticles for drug delivery. Elsevier; 2024. pp. 495\u2013509.","DOI":"10.1016\/B978-0-443-19061-2.00010-9"},{"key":"3741_CR187","doi-asserted-by":"crossref","unstructured":"Mousavi R, Soltani M, Souri M. Microneedle patch capable of dual drug release for drug delivery to brain tumors. Drug Delivery and Translational Research; 2024. pp. 1\u201328.","DOI":"10.1007\/s13346-024-01696-6"},{"issue":"1","key":"3741_CR188","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41540-024-00467-w","volume":"10","author":"M Souri","year":"2024","unstructured":"Souri M, et al. Enhancing localized chemotherapy with anti-angiogenesis and nanomedicine synergy for improved tumor penetration in well-vascularized tumors. Npj Syst Biology Appl. 2024;10(1):136.","journal-title":"Npj Syst Biology Appl"},{"issue":"1","key":"3741_CR189","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Experimental Hematol Oncol. 2023;12(1):99.","journal-title":"Experimental Hematol Oncol"},{"issue":"5","key":"3741_CR190","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1002\/cti2.1132","volume":"9","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single\u2010cell analysis. Clin Translational Immunol. 2020;9(5):e1132.","journal-title":"Clin Translational Immunol"},{"issue":"10","key":"3741_CR191","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella LV, et al. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012;12(10):2575\u201387.","journal-title":"Am J Transplant"},{"key":"3741_CR192","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","volume":"10","author":"W Qin","year":"2019","unstructured":"Qin W, et al. The diverse function of PD-1\/PD-L pathway beyond cancer. Front Immunol. 2019;10:2298.","journal-title":"Front Immunol"},{"key":"3741_CR193","doi-asserted-by":"publisher","first-page":"1136169","DOI":"10.3389\/fimmu.2023.1136169","volume":"14","author":"YF Huang","year":"2023","unstructured":"Huang YF, et al. Causal relationships between gut microbiota and programmed cell death protein 1\/programmed cell death-ligand 1: A bidirectional Mendelian randomization study. Front Immunol. 2023;14:1136169.","journal-title":"Front Immunol"},{"issue":"2","key":"3741_CR194","first-page":"41","volume":"4","author":"S Hatami","year":"2023","unstructured":"Hatami S, et al. The role of human Platelet-rich plasma in burn injury patients: A single center study. Canon J Med. 2023;4(2):41\u20135.","journal-title":"Canon J Med"},{"key":"3741_CR195","doi-asserted-by":"publisher","first-page":"100177","DOI":"10.1016\/j.clinsp.2023.100177","volume":"78","author":"B Gutic","year":"2023","unstructured":"Gutic B, et al. Programmed cell death-1 and its ligands: current knowledge and possibilities in immunotherapy. Clinics. 2023;78:100177.","journal-title":"Clinics"},{"issue":"2","key":"3741_CR196","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/713774061","volume":"9","author":"MJ Eppihimer","year":"2002","unstructured":"Eppihimer MJ, et al. Expression and regulation of the PD-L1 Immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 2002;9(2):133\u201345.","journal-title":"Microcirculation"},{"issue":"4","key":"3741_CR197","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","volume":"20","author":"D Daassi","year":"2020","unstructured":"Daassi D, Mahoney KM, Freeman GJ. The importance of Exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20(4):209\u201315.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3741_CR198","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","volume":"11","author":"R Tremblay-LeMay","year":"2018","unstructured":"Tremblay-LeMay R, Rastgoo N, Chang H. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway. J Hematol Oncol. 2018;11(1):46.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3741_CR199","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11(11):955.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3741_CR200","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/cei.13594","volume":"205","author":"Z Liu","year":"2021","unstructured":"Liu Z, et al. Bone marrow-derived mesenchymal stem cells inhibit CD8(+) T cell immune responses via PD-1\/PD-L1 pathway in multiple myeloma. Clin Exp Immunol. 2021;205(1):53\u201362.","journal-title":"Clin Exp Immunol"},{"key":"3741_CR201","doi-asserted-by":"crossref","unstructured":"Razavi Z-S et al. Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective. Front Bioeng Biotechnol, 2024. 12.","DOI":"10.3389\/fbioe.2024.1385124"},{"issue":"7","key":"3741_CR202","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/15384101.2018.1442624","volume":"17","author":"D Chen","year":"2018","unstructured":"Chen D, et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1\/PD-L1 pathway. Cell Cycle. 2018;17(7):858\u201367.","journal-title":"Cell Cycle"},{"issue":"13","key":"3741_CR203","first-page":"2286","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson Jr DM, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody. Blood. J Am Soc Hematol. 2010;116(13):2286\u201394.","journal-title":"J Am Soc Hematol"},{"issue":"20","key":"3741_CR204","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G G\u00f6rg\u00fcn","year":"2015","unstructured":"G\u00f6rg\u00fcn G, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607\u201318.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3741_CR205","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","volume":"17","author":"WH Hallett","year":"2011","unstructured":"Hallett WH, et al. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 Blockade. Biol Blood Marrow Transplant. 2011;17(8):1133\u201345.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"3741_CR206","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/leu.2015.79","volume":"29","author":"B Paiva","year":"2015","unstructured":"Paiva B, et al. PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 Blockade in multiple myeloma. Leukemia. 2015;29(10):2110\u20133.","journal-title":"Leukemia"},{"issue":"23","key":"3741_CR207","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698\u2013704.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3741_CR208","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200(2):108\u201319.","journal-title":"Clin Exp Immunol"},{"key":"3741_CR209","doi-asserted-by":"crossref","unstructured":"Lee BH et al. PVR (CD155) expression as a potential prognostic marker in multiple myeloma. Biomedicines, 2022. 10(5).","DOI":"10.3390\/biomedicines10051099"},{"issue":"3","key":"3741_CR210","first-page":"78","volume":"4","author":"S Hatami","year":"2023","unstructured":"Hatami S, et al. Evaluation the effect of lipofilling in burn Scar: A cross-sectional study. Canon J Med. 2023;4(3):78\u201382.","journal-title":"Canon J Med"},{"issue":"7","key":"3741_CR211","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1002\/ctm2.861","volume":"12","author":"ZY Liu","year":"2022","unstructured":"Liu ZY, et al. CD155\/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma. Clin Transl Med. 2022;12(7):e861.","journal-title":"Clin Transl Med"},{"issue":"16","key":"3741_CR212","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","volume":"132","author":"C Guillerey","year":"2018","unstructured":"Guillerey C, et al. TIGIT immune checkpoint Blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood. 2018;132(16):1689\u201394.","journal-title":"Blood"},{"issue":"1","key":"3741_CR213","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12(1):99.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"3741_CR214","doi-asserted-by":"publisher","first-page":"18007","DOI":"10.1038\/s41598-024-69119-7","volume":"14","author":"A Sarmadi","year":"2024","unstructured":"Sarmadi A, et al. Comparative analysis of vision Transformers and convolutional neural networks in osteoporosis detection from X-ray images. Sci Rep. 2024;14(1):18007.","journal-title":"Sci Rep"},{"key":"3741_CR215","unstructured":"Davis LN. Strategies to overcome Immunomodulatory drug resistance in multiple myeloma. University of Colorado Denver, Anschutz Medical Campus; 2024."},{"key":"3741_CR216","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","volume":"1248","author":"S Van Coillie","year":"2020","unstructured":"Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol. 2020;1248:7\u201332.","journal-title":"Adv Exp Med Biol"},{"key":"3741_CR217","doi-asserted-by":"crossref","unstructured":"Gaber T et al. CTLA-4 mediates inhibitory function of mesenchymal stem\/stromal cells. Int J Mol Sci, 2018. 19(8).","DOI":"10.3390\/ijms19082312"},{"issue":"1","key":"3741_CR218","first-page":"58","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood J Am Soc Hematol. 2018;131(1):58\u201367.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"3741_CR219","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/ijms24065730","volume":"24","author":"A de Kulikowska","year":"2023","unstructured":"de Kulikowska A, et al. Inappropriate expression of PD-1 and CTLA-4 checkpoints in myeloma patients is more pronounced at diagnosis: implications for time to progression and response to therapeutic checkpoint inhibitors. Int J Mol Sci. 2023;24(6):5730.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3741_CR220","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","volume":"63","author":"WM Braga","year":"2014","unstructured":"Braga WM, et al. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother. 2014;63(11):1189\u201397.","journal-title":"Cancer Immunol Immunother"},{"key":"3741_CR221","doi-asserted-by":"crossref","unstructured":"Nawar N et al. Social media for exploring adverse drug events associated with multiple sclerosis. 2022.","DOI":"10.24251\/HICSS.2022.515"},{"key":"3741_CR222","doi-asserted-by":"crossref","unstructured":"Cui J-W, et al. Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Volume 171. Biomedicine & Pharmacotherapy; 2024. p. 116203.","DOI":"10.1016\/j.biopha.2024.116203"},{"key":"3741_CR223","unstructured":"Liu J et al. Prediction of Patient Willingness to Recommend Hospital: A Machine Learning-Based Exploratory Study. 2021."},{"issue":"4","key":"3741_CR224","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jclinpath-2021-207789","volume":"75","author":"L Bolm","year":"2022","unstructured":"Bolm L, et al. Gene of the month: T-cell immunoreceptor with Immunoglobulin and ITIM domains (TIGIT). J Clin Pathol. 2022;75(4):217\u201321.","journal-title":"J Clin Pathol"},{"issue":"1","key":"3741_CR225","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14728214.2024.2313650","volume":"29","author":"A Shamabadi","year":"2024","unstructured":"Shamabadi A, et al. Emerging drugs for the treatment of irritability associated with autism spectrum disorder. Expert Opin Emerg Drugs. 2024;29(1):45\u201356.","journal-title":"Expert Opin Emerg Drugs"},{"key":"3741_CR226","doi-asserted-by":"publisher","first-page":"107458","DOI":"10.1016\/j.phrs.2024.107458","volume":"209","author":"J Zhang","year":"2024","unstructured":"Zhang J, et al. The role of Tim-3 Blockade in the tumor immune microenvironment beyond T cells. Pharmacol Res. 2024;209:107458.","journal-title":"Pharmacol Res"},{"issue":"39","key":"3741_CR227","doi-asserted-by":"publisher","first-page":"e39622","DOI":"10.1097\/MD.0000000000039622","volume":"103","author":"J Nie","year":"2024","unstructured":"Nie J, et al. Exploring the molecular landscape of lymphocyte activation gene-3: A literature review. Medicine. 2024;103(39):e39622.","journal-title":"Medicine"},{"issue":"17","key":"3741_CR228","doi-asserted-by":"publisher","first-page":"e37060","DOI":"10.1016\/j.heliyon.2024.e37060","volume":"10","author":"Y Deng","year":"2024","unstructured":"Deng Y, et al. Eliminating a barrier: aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment. Heliyon. 2024;10(17):e37060.","journal-title":"Heliyon"},{"key":"3741_CR229","doi-asserted-by":"publisher","first-page":"116675","DOI":"10.1016\/j.biopha.2024.116675","volume":"175","author":"K Wojciechowicz","year":"2024","unstructured":"Wojciechowicz K, et al. Targeting BTLA with the peptide inhibitor HVEM(14\u201339)\u2013 A new way to restore the activity of T cells in melanoma. Biomed Pharmacother. 2024;175:116675.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3741_CR230","first-page":"e33","volume":"12","author":"M Motavaselian","year":"2024","unstructured":"Motavaselian M, et al. Diagnostic performance of ultrasonography for identification of small bowel obstruction; a systematic review and Meta-analysis. Arch Acad Emerg Med. 2024;12(1):e33.","journal-title":"Arch Acad Emerg Med"},{"issue":"1","key":"3741_CR231","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/s41598-023-28870-z","volume":"13","author":"S Tanikawa","year":"2023","unstructured":"Tanikawa S, et al. Engineering of an electrically charged hydrogel implanted into a traumatic brain injury model for Stepwise neuronal tissue reconstruction. Sci Rep. 2023;13(1):2233.","journal-title":"Sci Rep"},{"issue":"1","key":"3741_CR232","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12935-024-03293-6","volume":"24","author":"A Zabeti Touchaei","year":"2024","unstructured":"Zabeti Touchaei A, Vahidi S. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1\/PD-L1 and CTLA-4 pathways. Cancer Cell Int. 2024;24(1):102.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"3741_CR233","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27(3):491\u2013503.","journal-title":"Nat Med"},{"issue":"29","key":"3741_CR234","doi-asserted-by":"publisher","first-page":"20563","DOI":"10.18632\/oncotarget.25003","volume":"9","author":"A Lamanuzzi","year":"2018","unstructured":"Lamanuzzi A, et al. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. Oncotarget. 2018;9(29):20563\u201377.","journal-title":"Oncotarget"},{"issue":"1","key":"3741_CR235","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neo.2018.10.011","volume":"21","author":"I Saltarella","year":"2019","unstructured":"Saltarella I, et al. Homotypic and heterotypic activation of the Notch pathway in multiple Myeloma-Enhanced angiogenesis: A novel therapeutic target?? Neoplasia. 2019;21(1):93\u2013105.","journal-title":"Neoplasia"},{"key":"3741_CR236","doi-asserted-by":"crossref","unstructured":"Saltarella I et al. Mechanisms of resistance to Anti-CD38 daratumumab in multiple myeloma. Cells, 2020. 9(1).","DOI":"10.3390\/cells9010167"},{"key":"3741_CR237","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, et al. Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche. Front Oncol. 2022;12:973836.","journal-title":"Front Oncol"},{"issue":"1","key":"3741_CR238","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/0008-5472.CAN-23-0189","volume":"84","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. Hypoxic bone marrow stromal cells secrete miR-140\u20135p and miR-28\u20133p that target SPRED1 to confer drug resistance in multiple myeloma. Cancer Res. 2024;84(1):39\u201355.","journal-title":"Cancer Res"},{"issue":"7","key":"3741_CR239","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3324\/haematol.2016.154062","volume":"102","author":"J Pang","year":"2017","unstructured":"Pang J, et al. Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression. Haematologica. 2017;102(7):1273\u201380.","journal-title":"Haematologica"},{"issue":"10","key":"3741_CR240","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3109\/10428194.2011.591004","volume":"52","author":"X Wang","year":"2011","unstructured":"Wang X, et al. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma. 2011;52(10):1991\u20138.","journal-title":"Leuk Lymphoma"},{"key":"3741_CR241","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-4-37","volume":"4","author":"M Hao","year":"2011","unstructured":"Hao M, et al. Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol. 2011;4:1\u20133.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3741_CR242","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-020-0304-7","volume":"10","author":"S Rajeev Krishnan","year":"2020","unstructured":"Rajeev Krishnan S, et al. A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer J. 2020;10(3):37.","journal-title":"Blood Cancer J"},{"key":"3741_CR243","doi-asserted-by":"publisher","first-page":"107574","DOI":"10.1016\/j.compbiomed.2023.107574","volume":"166","author":"MK Shahvandi","year":"2023","unstructured":"Shahvandi MK, et al. A comparative study between conventional chemotherapy and photothermal activated nano-sized targeted drug delivery to solid tumor. Comput Biol Med. 2023;166:107574.","journal-title":"Comput Biol Med"},{"issue":"1","key":"3741_CR244","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41598-024-52003-9","volume":"14","author":"A Hosseinpour","year":"2024","unstructured":"Hosseinpour A, Soltani M, Souri M. Improving tumor treatment through intratumoral injection of drug-loaded magnetic nanoparticles and low-intensity ultrasound. Sci Rep. 2024;14(1):1452.","journal-title":"Sci Rep"},{"issue":"1","key":"3741_CR245","first-page":"e81","volume":"10","author":"M Motavaselian","year":"2022","unstructured":"Motavaselian M, et al. Diagnostic performance of magnetic resonance imaging for detection of acute appendicitis in pregnant women; a systematic review and Meta-Analysis. Arch Acad Emerg Med. 2022;10(1):e81.","journal-title":"Arch Acad Emerg Med"},{"issue":"1","key":"3741_CR246","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3892\/etm.2021.10137","volume":"22","author":"J Ning","year":"2021","unstructured":"Ning J, et al. HMGB1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-\u03baB pathway. Exp Ther Med. 2021;22(1):705.","journal-title":"Exp Ther Med"},{"key":"3741_CR247","doi-asserted-by":"publisher","first-page":"105519","DOI":"10.1016\/j.jddst.2024.105519","volume":"94","author":"M Souri","year":"2024","unstructured":"Souri M, Elahi S, Soltani M. Intratumoral implantable drug delivery system for targeted localized chemotherapy in breast cancer. J Drug Deliv Sci Technol. 2024;94:105519.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"3741_CR248","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/17425247.2024.2323211","volume":"21","author":"M Souri","year":"2024","unstructured":"Souri M, Elahi S, Soltani M. Programmable intratumoral drug delivery to breast cancer using wireless bioelectronic device with electrochemical actuation. Expert Opin Drug Deliv. 2024;21(3):495\u2013511.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"3741_CR249","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/leu.2010.225","volume":"25","author":"L Liu","year":"2011","unstructured":"Liu L, et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 2011;25(1):23\u201331.","journal-title":"Leukemia"},{"issue":"1","key":"3741_CR250","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13046-018-0883-3","volume":"37","author":"X Guo","year":"2018","unstructured":"Guo X, et al. HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair. J Exp Clin Cancer Res. 2018;37(1):205.","journal-title":"J Exp Clin Cancer Res"},{"key":"3741_CR251","doi-asserted-by":"crossref","unstructured":"Wyld L et al. Senescence and cancer: A review of clinical implications of senescence and senotherapies. Cancers (Basel), 2020. 12(8).","DOI":"10.3390\/cancers12082134"},{"key":"3741_CR252","doi-asserted-by":"publisher","first-page":"722205","DOI":"10.3389\/fcell.2021.722205","volume":"9","author":"J Yang","year":"2021","unstructured":"Yang J, et al. The Paradoxical role of cellular senescence in cancer. Front Cell Dev Biology. 2021;9:722205.","journal-title":"Front Cell Dev Biology"},{"key":"3741_CR253","doi-asserted-by":"publisher","first-page":"114310","DOI":"10.1016\/j.ejpb.2024.114310","volume":"199","author":"M Souri","year":"2024","unstructured":"Souri M, Golzaryan A, Soltani M. Charge-Switchable nanoparticles to enhance tumor penetration and accumulation. Eur J Pharm Biopharm. 2024;199:114310.","journal-title":"Eur J Pharm Biopharm"},{"key":"3741_CR254","doi-asserted-by":"publisher","first-page":"1320371","DOI":"10.3389\/fonc.2024.1320371","volume":"14","author":"A Piranfar","year":"2024","unstructured":"Piranfar A, et al. Localized radiotherapy of solid tumors using radiopharmaceutical loaded implantable system: insights from a mathematical model. Front Oncol. 2024;14:1320371.","journal-title":"Front Oncol"},{"issue":"3","key":"3741_CR255","doi-asserted-by":"publisher","first-page":"e59756","DOI":"10.1371\/journal.pone.0059756","volume":"8","author":"T Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 T, et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS ONE. 2013;8(3):e59756.","journal-title":"PLoS ONE"},{"issue":"6","key":"3741_CR256","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","volume":"22","author":"MME de Jong","year":"2021","unstructured":"de Jong MME, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021;22(6):769\u201380.","journal-title":"Nat Immunol"},{"issue":"10","key":"3741_CR257","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/s41375-022-01653-7","volume":"36","author":"F Seymour","year":"2022","unstructured":"Seymour F, et al. Immune senescence in multiple myeloma-a role for mitochondrial dysfunction? Leukemia. 2022;36(10):2368\u201373.","journal-title":"Leukemia"},{"key":"3741_CR258","doi-asserted-by":"crossref","unstructured":"Fakouri A, et al. Applications of mesenchymal stem cell-exosome components in wound infection healing: new insights. Volume 12. Burns & Trauma; 2024. p. tkae021.","DOI":"10.1093\/burnst\/tkae021"},{"key":"3741_CR259","unstructured":"Weivoda MD, Matthew M, Andersen, Thomas TL. Role of senescence in multiple myeloma tumorigenesis. mayoclinic; 2021."},{"key":"3741_CR260","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1078-3","volume":"15","author":"R Berenstein","year":"2015","unstructured":"Berenstein R, et al. Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region. BMC Cancer. 2015;15:1\u201313.","journal-title":"BMC Cancer"},{"issue":"8","key":"3741_CR261","first-page":"1","volume":"6","author":"S Farokhi","year":"2024","unstructured":"Farokhi S, et al. New perspectives on arteriosclerosis treatment using nanoparticles and mesenchymal stem cells. Discover Appl Sci. 2024;6(8):1\u201340.","journal-title":"Discover Appl Sci"},{"issue":"3","key":"3741_CR262","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/stem.2499","volume":"35","author":"M Kanehira","year":"2017","unstructured":"Kanehira M, et al. A lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma. Stem Cells. 2017;35(3):739\u201353.","journal-title":"Stem Cells"},{"key":"3741_CR263","doi-asserted-by":"crossref","unstructured":"Magkrioti C, Kaffe E, Aidinis V. The Role of Autotaxin and LPA Signaling in Embryonic Development, Pathophysiology and Cancer. 2023, MDPI. p. 8325.","DOI":"10.3390\/ijms24098325"},{"issue":"3","key":"3741_CR264","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/stem.2499","volume":"35","author":"M Kanehira","year":"2017","unstructured":"Kanehira M, et al. An lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma. Stem Cells. 2017;35(3):739\u201353.","journal-title":"Stem Cells"},{"key":"3741_CR265","doi-asserted-by":"crossref","unstructured":"Cao YJ et al. MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors. J Oncol, 2022. 2022: p. 4705654.","DOI":"10.1155\/2022\/4705654"},{"key":"3741_CR266","doi-asserted-by":"publisher","first-page":"584683","DOI":"10.3389\/fonc.2020.584683","volume":"10","author":"H Fairfield","year":"2020","unstructured":"Fairfield H, et al. Multiple myeloma cells alter adipogenesis, increase Senescence-Related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2020;10:584683.","journal-title":"Front Oncol"},{"key":"3741_CR267","doi-asserted-by":"publisher","first-page":"874325","DOI":"10.3389\/fonc.2022.874325","volume":"12","author":"L Heinemann","year":"2022","unstructured":"Heinemann L, et al. Inhibiting PI3K-AKT-mTOR signaling in multiple myeloma-Associated mesenchymal stem cells impedes the proliferation of multiple myeloma cells. Front Oncol. 2022;12:874325.","journal-title":"Front Oncol"},{"key":"3741_CR268","doi-asserted-by":"crossref","unstructured":"Da Ros F et al. IRE1a-Induced filamina phosphorylation enhances migration of mesenchymal stem cells derived from multiple myeloma patients. Cells, 2023. 12(15).","DOI":"10.3390\/cells12151935"},{"key":"3741_CR269","doi-asserted-by":"crossref","unstructured":"Gebraad A et al. Growth response and differentiation of bone Marrow-Derived mesenchymal stem\/stromal cells in the presence of novel multiple myeloma drug Melflufen. Cells, 2022. 11(9).","DOI":"10.3390\/cells11091574"},{"key":"3741_CR270","doi-asserted-by":"publisher","first-page":"862524","DOI":"10.3389\/fcell.2022.862524","volume":"10","author":"J Gu","year":"2022","unstructured":"Gu J, et al. Exosomal miR-483-5p in bone marrow mesenchymal stem cells promotes malignant progression of multiple myeloma by targeting TIMP2. Front Cell Dev Biol. 2022;10:862524.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"3741_CR271","first-page":"254","volume":"38","author":"\u0130 Y\u0131lmaz Ba\u015faran","year":"2021","unstructured":"Y\u0131lmaz Ba\u015faran \u0130, Kara\u00f6z E. Generation of induced pluripotent stem cells from patients with multiple myeloma. Turk J Haematol. 2021;38(4):254\u201363.","journal-title":"Turk J Haematol"},{"issue":"8","key":"3741_CR272","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.4252\/wjsc.v13.i8.1094","volume":"13","author":"V Dupuis","year":"2021","unstructured":"Dupuis V, Oltra E. Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: mesenchymal stem cells from induced pluripotent stem cells. World J Stem Cells. 2021;13(8):1094\u2013111.","journal-title":"World J Stem Cells"},{"issue":"1","key":"3741_CR273","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00403-024-03790-8","volume":"317","author":"ZS Razavi","year":"2025","unstructured":"Razavi ZS, et al. Application of novel strategies in chronic wound management with focusing on pressure ulcers: new perspective. Arch Dermatol Res. 2025;317(1):320.","journal-title":"Arch Dermatol Res"},{"issue":"15","key":"3741_CR274","doi-asserted-by":"publisher","first-page":"11227","DOI":"10.1074\/jbc.M109.086389","volume":"285","author":"J Cai","year":"2010","unstructured":"Cai J, et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. J Biol Chem. 2010;285(15):11227\u201334.","journal-title":"J Biol Chem"},{"issue":"3","key":"3741_CR275","doi-asserted-by":"publisher","first-page":"e17610","DOI":"10.1371\/journal.pone.0017610","volume":"6","author":"K Niibe","year":"2011","unstructured":"Niibe K, et al. Purified mesenchymal stem cells are an efficient source for iPS cell induction. PLoS ONE. 2011;6(3):e17610.","journal-title":"PLoS ONE"},{"issue":"24","key":"3741_CR276","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-12-2664","volume":"72","author":"J He","year":"2012","unstructured":"He J, et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 2012;72(24):6393\u2013402.","journal-title":"Cancer Res"},{"key":"3741_CR277","doi-asserted-by":"crossref","unstructured":"Liu H et al. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Science translational medicine, 2016. 8(353): p. 353ra113-353ra113.","DOI":"10.1126\/scitranslmed.aad8949"},{"issue":"8","key":"3741_CR278","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nrrheum.2009.137","volume":"5","author":"I Takada","year":"2009","unstructured":"Takada I, Kouzmenko AP, Kato S. Wnt and PPAR\u03b3 signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol. 2009;5(8):442\u20137.","journal-title":"Nat Rev Rheumatol"},{"key":"3741_CR279","doi-asserted-by":"crossref","unstructured":"Liu Z et al. Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells. Sci Signal, 2020. 13(633).","DOI":"10.1126\/scisignal.aay8203"},{"issue":"3","key":"3741_CR280","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1210\/jc.2012-3634","volume":"98","author":"PK Fazeli","year":"2013","unstructured":"Fazeli PK, et al. Marrow fat and bone\u2014new perspectives. J Clin Endocrinol Metabolism. 2013;98(3):935\u201345.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"11","key":"3741_CR281","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.ajpath.2016.07.012","volume":"186","author":"TN Trotter","year":"2016","unstructured":"Trotter TN, et al. Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone. Am J Pathol. 2016;186(11):3054\u201363.","journal-title":"Am J Pathol"},{"issue":"494","key":"3741_CR282","doi-asserted-by":"publisher","first-page":"eaau9087","DOI":"10.1126\/scitranslmed.aau9087","volume":"11","author":"H Liu","year":"2019","unstructured":"Liu H, et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019;11(494):eaau9087.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3741_CR283","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11033-024-09250-w","volume":"51","author":"G Taheripak","year":"2024","unstructured":"Taheripak G, et al. SIRT1 activation attenuates palmitate induced apoptosis in C2C12 muscle cells. Mol Biol Rep. 2024;51(1):354.","journal-title":"Mol Biol Rep"},{"issue":"11","key":"3741_CR284","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.3390\/ijms21113854","volume":"21","author":"L Lemaitre","year":"2020","unstructured":"Lemaitre L, et al. Imprinting of mesenchymal stromal cell transcriptome persists even after treatment in patients with multiple myeloma. Int J Mol Sci. 2020;21(11):3854.","journal-title":"Int J Mol Sci"},{"key":"3741_CR285","doi-asserted-by":"publisher","first-page":"584683","DOI":"10.3389\/fonc.2020.584683","volume":"10","author":"H Fairfield","year":"2021","unstructured":"Fairfield H, et al. Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2021;10:584683.","journal-title":"Front Oncol"},{"key":"3741_CR286","doi-asserted-by":"crossref","unstructured":"Liu H et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med, 2019. 11(494).","DOI":"10.1126\/scitranslmed.aau9087"},{"issue":"4","key":"3741_CR287","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","volume":"15","author":"IM Ghobrial","year":"2018","unstructured":"Ghobrial IM, et al. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018;15(4):219\u201333.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"3741_CR288","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","volume":"20","author":"S M\u00e9ndez-Ferrer","year":"2020","unstructured":"M\u00e9ndez-Ferrer S, et al. Bone marrow niches in haematological malignancies. Nat Rev Cancer. 2020;20(5):285\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3741_CR289","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","volume":"21","author":"J Corre","year":"2007","unstructured":"Corre J, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007;21(5):1079\u201388.","journal-title":"Leukemia"},{"issue":"8","key":"3741_CR290","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/leu.2009.65","volume":"23","author":"M Garayoa","year":"2009","unstructured":"Garayoa M, et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia. 2009;23(8):1515\u201327.","journal-title":"Leukemia"},{"issue":"2","key":"3741_CR291","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","volume":"13","author":"A Garc\u00eda-Ortiz","year":"2021","unstructured":"Garc\u00eda-Ortiz A, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers. 2021;13(2):217.","journal-title":"Cancers"},{"key":"3741_CR292","doi-asserted-by":"crossref","unstructured":"Elahi KC et al. Human Mesenchymal Stromal Cells from Different Sources Diverge in Their Expression of Cell Surface Proteins and Display Distinct Differentiation Patterns. Stem Cells Int, 2016. 2016: p. 5646384.","DOI":"10.1155\/2016\/5646384"},{"issue":"5","key":"3741_CR293","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.mad.2012.03.014","volume":"133","author":"M Kim","year":"2012","unstructured":"Kim M, et al. Age-related alterations in mesenchymal stem cells related to shift in differentiation from osteogenic to adipogenic potential: implication to age-associated bone diseases and defects. Mech Ageing Dev. 2012;133(5):215\u201325.","journal-title":"Mech Ageing Dev"},{"issue":"6","key":"3741_CR294","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/aps.2013.50","volume":"34","author":"X Wei","year":"2013","unstructured":"Wei X, et al. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747\u201354.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"3741_CR295","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10522-011-9344-5","volume":"12","author":"LJ Dominguez","year":"2011","unstructured":"Dominguez LJ, et al. Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology. 2011;12(5):397\u2013408.","journal-title":"Biogerontology"},{"key":"3741_CR296","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jbo.2018.09.001","volume":"13","author":"J Adamik","year":"2018","unstructured":"Adamik J, Galson DL, Roodman GD. Osteoblast suppression in multiple myeloma bone disease. J Bone Oncol. 2018;13:62\u201370.","journal-title":"J Bone Oncol"},{"issue":"5","key":"3741_CR297","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3390\/ijms25052527","volume":"25","author":"C-H Wu","year":"2024","unstructured":"Wu C-H, et al. Biology and therapeutic properties of mesenchymal stem cells in leukemia. Int J Mol Sci. 2024;25(5):2527.","journal-title":"Int J Mol Sci"},{"key":"3741_CR298","doi-asserted-by":"crossref","unstructured":"Tang J et al. The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics. MedComm (2020), 2024. 5(8): p. e663.","DOI":"10.1002\/mco2.663"},{"issue":"49","key":"3741_CR299","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1038\/s41388-024-03183-1","volume":"43","author":"R Antoon","year":"2024","unstructured":"Antoon R, et al. Mesenchymal stromal cells as cancer promoters. Oncogene. 2024;43(49):3545\u201355.","journal-title":"Oncogene"},{"issue":"1","key":"3741_CR300","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13045-021-01208-w","volume":"14","author":"T Lan","year":"2021","unstructured":"Lan T, Luo M, Wei X. Mesenchymal stem\/stromal cells in cancer therapy. J Hematol Oncol. 2021;14(1):195.","journal-title":"J Hematol Oncol"},{"key":"3741_CR301","doi-asserted-by":"crossref","unstructured":"Velikova T, Dekova T, Miteva DG. Controversies regarding transplantation of mesenchymal stem cells. World J Transplantation, 2024. 14(2).","DOI":"10.5500\/wjt.v14.i2.90554"},{"key":"3741_CR302","doi-asserted-by":"publisher","first-page":"969178","DOI":"10.3389\/fcell.2022.969178","volume":"10","author":"J Oliva","year":"2022","unstructured":"Oliva J, et al. Editorial: mesenchymal stromal cells: preclinical and clinical challenges. Front Cell Dev Biol. 2022;10:969178.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3741_CR303","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-021-01037-x","volume":"14","author":"T Zhou","year":"2021","unstructured":"Zhou T, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14(1):24.","journal-title":"J Hematol Oncol"},{"key":"3741_CR304","doi-asserted-by":"crossref","unstructured":"Wang L et al. Inflammatory bone marrow mesenchymal stem cells in multiple myeloma: transcriptional signature and in vitro modeling. Cancers (Basel), 2023. 15(21).","DOI":"10.3390\/cancers15215148"},{"issue":"1","key":"3741_CR305","first-page":"59","volume":"10","author":"D Xiong","year":"2023","unstructured":"Xiong D, Zhang L, Sun ZJ. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Mil Med Res. 2023;10(1):59.","journal-title":"Mil Med Res"},{"key":"3741_CR306","unstructured":"Jamshidi B, Ghorbani N, Rostamy-Malkhalifeh M. Optimizing Lung Cancer Detection in CT Imaging: A Wavelet Multi-Layer Perceptron (WMLP) Approach Enhanced by Dragonfly Algorithm (DA). arXiv preprint arXiv:2408.15355, 2024."},{"key":"3741_CR307","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, et al. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. eBioMedicine. 2024;106:105266.","journal-title":"eBioMedicine"},{"issue":"1","key":"3741_CR308","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/ijms24010563","volume":"24","author":"KA Skelding","year":"2023","unstructured":"Skelding KA, et al. Bone marrow microenvironment as a source of new drug targets for the treatment of acute myeloid leukaemia. Int J Mol Sci. 2023;24(1):563.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3741_CR309","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s40001-023-01556-y","volume":"28","author":"R Abbasi","year":"2023","unstructured":"Abbasi R, et al. Mesenchymal stem cells-derived exosomes: novel carriers for nanoparticle to combat cancer. Eur J Med Res. 2023;28(1):579.","journal-title":"Eur J Med Res"},{"issue":"4","key":"3741_CR310","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/ijms24043136","volume":"24","author":"F De Luca","year":"2023","unstructured":"De Luca F, et al. Monoclonal antibodies: the greatest resource to treat multiple myeloma. Int J Mol Sci. 2023;24(4):3136.","journal-title":"Int J Mol Sci"},{"key":"3741_CR311","doi-asserted-by":"crossref","unstructured":"Sadat Razavi Z et al. Advancing neurological disorders therapies: organic nanoparticles as a key to blood-brain barrier penetration. Int J Pharm, 2025: p. 125186.","DOI":"10.1016\/j.ijpharm.2025.125186"},{"issue":"1","key":"3741_CR312","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1186\/s12885-022-09775-y","volume":"22","author":"A Salimi","year":"2022","unstructured":"Salimi A, et al. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK. BMC Cancer. 2022;22(1):735.","journal-title":"BMC Cancer"},{"key":"3741_CR313","doi-asserted-by":"publisher","first-page":"1017990","DOI":"10.3389\/fimmu.2022.1017990","volume":"13","author":"H Guo","year":"2022","unstructured":"Guo H, et al. Reshaping the tumor microenvironment: the versatility of Immunomodulatory drugs in B-cell neoplasms. Front Immunol. 2022;13:1017990.","journal-title":"Front Immunol"},{"key":"3741_CR314","doi-asserted-by":"publisher","first-page":"106060","DOI":"10.1016\/j.phrs.2022.106060","volume":"176","author":"D Bjeli\u0107","year":"2022","unstructured":"Bjeli\u0107 D, Fin\u0161gar M. Bioactive coatings with anti-osteoclast therapeutic agents for bone implants: enhanced compliance and prolonged implant life. Pharmacol Res. 2022;176:106060.","journal-title":"Pharmacol Res"},{"issue":"1","key":"3741_CR315","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40001-025-02310-2","volume":"30","author":"A Shadab","year":"2025","unstructured":"Shadab A, et al. Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations. Eur J Med Res. 2025;30(1):71.","journal-title":"Eur J Med Res"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03741-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:38:56Z","timestamp":1743305936000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03741-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":315,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3741"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03741-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}